Soluble receptor activator of nuclear factor-kB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation

Clinical Rheumatology

Volumn 29, Issue 10, 2010, Pages 1155-1161

  Chen, Chun Hsiung ^a,b   Chen, Hung An ^c   Liao, Hsien Tzung ^b,d   Liu, Chin Hsiu ^a   Tsai, Chang Youh ^b   Chou, Chung Tei ^b,e  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Ankylosing spondylitis; Inflammation; OPG; Physical mobility; RANKL

Indexed keywords

C REACTIVE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; SEVESO ACCIDENT;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RANGE OF MOTION, ARTICULAR; RANK LIGAND; SEVESO ACCIDENTAL RELEASE; SPONDYLITIS, ANKYLOSING; STATISTICS, NONPARAMETRIC;

EID: 79952113849     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-010-1543-y     Document Type: Article

References (26)

1. Zochling J, Brandt J, Braun J (2005) The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) 44:1483-1491
2. Toussirot E, Wendling D (1996) Osteoporosis in ankylosing spondylitis. Presse Méd 25:720-724
3. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M et al (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-Terminal kinase in T cells. J Biol Chem 272:25190-25194
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
5. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
6. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al (1990) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323
7. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309
8. Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C (1998) Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: downregulation by glucocorticoids. J Endocrinol 159:191-195
9. Kim HR, Lee SH, Kim HY (2006) Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 45:1197-1200
10. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
11. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291
12. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
13. Jones SD, Steiner A, Garrett SL, Calin A (1996) The bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35:66-71
14. Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C et al (2008) Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int 28:987-993
15. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D (2008) The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 58:718-729
16. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W et al (2002) Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29:1430-1436
17. Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 31:2236-2241
18. Sarma PK, Misra R, Aggarwal A (2008) Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol 27:289-294
19. Sheehan NJ, Slavin BM, Donovan MP, Mount JN, Mathews JA (1986) Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 25:171-174
20. Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966-970
21. Hofbauer LC, Schoppet M, Christ M, Teichmann J, Lange U (2006) Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology (Oxford) 45:1218-1222
22. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS et al (2005) Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 108:237-243
23. Gannagé-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M et al (2008) Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 158:353-359
24. Yaturu S, Rains J, Jain SK (2008) Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-Alpha levels in men with type 2 diabetes. Cytokine 44:168-171
25. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA et al (2005) Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 67:1576-1582
26. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H (2003) The progression of vascular calcification and serum osteoprotegerin levels in patients on long-Term hemodialysis. Am J Kidney Dis 42:303-309